The Cat Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cat Allergy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cat Allergy and features dormant and discontinued products.

GlobalData tracks four drugs in development for Cat Allergy by four companies/universities/institutes. The top development phase for Cat Allergy is preclinical with two drugs in that stage. The Cat Allergy pipeline has four drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cat Allergy pipeline products market are: Amgen, Sementis and Angany.

The key targets in the Cat Allergy pipeline products market include Thymic Stromal Lymphopoietin (TSLP).

The key mechanisms of action in the Cat Allergy pipeline product include Thymic Stromal Lymphopoietin (TSLP) Inhibitor with one drug in Phase II. The Cat Allergy pipeline products include four routes of administration with the top ROA being Intradermal and three key molecule types in the Cat Allergy pipeline products market including Allergenics (Allergen), and Monoclonal Antibody.

Cat Allergy overview

Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing; runny or stuffy nose; facial pain (from nasal congestion); coughing; chest tightness; shortness of breath and wheezing; watery, red, or itchy eyes; and skin rash or hives.

For a complete picture of Cat Allergy’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.